VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

ALVAC-FL- env/gag EURIFEL FeLV FeLV DNA vaccine gag/pol and env
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004740
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env from FeLV-A/Glasgow gene engineering:
    • Type: Recombinant vector construction
    • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant protein preparation
    • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
    • Detailed Gene Information: Click Here.
  • Preparation: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes (Tartaglia et al., 1993).
  • Immunization Route: Intramuscular injection (i.m.)
  • Tradename: EURIFEL FeLV
  • Manufacturer: Merial
  • Vaccine Ontology ID: VO_0000918
  • Type: Recombinant vector vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Cat
  • Env from strain FRA gene engineering:
    • Type: Recombinant protein preparation
    • Description: Canarypox-based recombinant vaccine that expresses the FeLV env and gag protective genes (Poulet et al., 2003)
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant protein preparation
    • Description: Canarypox-based recombinant vaccine that expresses the FeLV env and gag protective genes (Poulet et al., 2003)
    • Detailed Gene Information: Click Here.
  • Vector: Canarypox virus
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Canarypox virus-vectored vaccine
  • Vaccine Ontology ID: VO_0004492
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Kitten
  • env from FeLV-A/Glasgow gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pUSE1 expressed two separate pUSE12 series constructs, one expressing FeLV gag/pol genes and the other expressing the FeLV subgroup A env gene (Hanlon et al., 2001).
    • Detailed Gene Information: Click Here.
  • Vector: pUSE1- is a mammalian expression vector derived from the vector pCI-neo (Promega) (Hanlon et al., 2001)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response

Cat Response

  • Vaccination Protocol: Cats were vaccinated with ALVAC-FL(dI IS) or ALVAC-FL, consisting of two subcutaneous inoculations of 108 PFU at 5 and 2 weeks prior to challenge (Tartaglia et al., 1993).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All cats were challenged by oronasal administration of 2 x 106 FFU of FeLV-A/Glasgow-1 isolate to simulate natural transmission (Tartaglia et al., 1993).
  • Efficacy: Although only 50% of the cats vaccinated with ALVAC-FL(dl IS) were protected against persistent viremia after oronasal exposure to a homologous FeLV isolate, all cats administered ALVAC-FL resisted the challenge exposure. Significantly, protection was afforded in the absence of detectable FeLV-neutralizing antibodies (Tartaglia et al., 1993).

Cat Response

  • Challenge Protocol: Oronasal FeLV challenge
  • Efficacy: The vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge (Poulet et al., 2003).

Cat Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: The vaccine consisting of FeLV DNA with the IL-12 and IL-18 genes conferred significant immunity, protecting completely against transient and persistent viremia, and in five of six kittens protecting against latent infection (Hanlon et al., 2001).
References References References
Tartaglia et al., 1993: Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. Journal of virology. 1993; 67(4); 2370-2375. [PubMed: 8383248].
Poulet et al., 2003: Poulet H, Brunet S, Boularand C, Guiot AL, Leroy V, Tartaglia J, Minke J, Audonnet JC, Desmettre P. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. The Veterinary record. 2003; 153(5); 141-145. [PubMed: 12934796].
Hanlon et al., 2001: Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, McDonald M, McGillivray C, Jarrett O, Neil JC, Onions DE. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. Journal of virology. 2001; 75(18); 8424-8433. [PubMed: 11507187].